![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NME1 |
Gene summary for NME1 |
![]() |
Gene information | Species | Human | Gene symbol | NME1 | Gene ID | 4830 |
Gene name | NME/NM23 nucleoside diphosphate kinase 1 | |
Gene Alias | AWD | |
Cytomap | 17q21.33 | |
Gene Type | protein-coding | GO ID | GO:0001678 | UniProtAcc | P15531 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4830 | NME1 | GSM4909281 | Human | Breast | IDC | 9.95e-08 | 3.53e-01 | 0.21 |
4830 | NME1 | GSM4909285 | Human | Breast | IDC | 2.28e-15 | 4.53e-01 | 0.21 |
4830 | NME1 | GSM4909286 | Human | Breast | IDC | 1.69e-27 | 5.09e-01 | 0.1081 |
4830 | NME1 | GSM4909287 | Human | Breast | IDC | 5.44e-03 | 2.98e-01 | 0.2057 |
4830 | NME1 | GSM4909288 | Human | Breast | IDC | 1.70e-03 | 2.13e-01 | 0.0988 |
4830 | NME1 | GSM4909290 | Human | Breast | IDC | 7.29e-13 | 5.42e-01 | 0.2096 |
4830 | NME1 | GSM4909294 | Human | Breast | IDC | 1.55e-12 | 4.65e-01 | 0.2022 |
4830 | NME1 | GSM4909297 | Human | Breast | IDC | 1.34e-07 | -1.36e-02 | 0.1517 |
4830 | NME1 | GSM4909298 | Human | Breast | IDC | 1.78e-03 | 2.18e-01 | 0.1551 |
4830 | NME1 | GSM4909307 | Human | Breast | IDC | 1.41e-08 | 3.85e-01 | 0.1569 |
4830 | NME1 | GSM4909308 | Human | Breast | IDC | 7.12e-19 | 5.31e-01 | 0.158 |
4830 | NME1 | GSM4909311 | Human | Breast | IDC | 2.09e-20 | 3.57e-04 | 0.1534 |
4830 | NME1 | GSM4909312 | Human | Breast | IDC | 3.64e-07 | 1.60e-01 | 0.1552 |
4830 | NME1 | GSM4909319 | Human | Breast | IDC | 1.90e-34 | 3.23e-02 | 0.1563 |
4830 | NME1 | GSM4909321 | Human | Breast | IDC | 2.22e-14 | 3.47e-01 | 0.1559 |
4830 | NME1 | brca1 | Human | Breast | Precancer | 1.43e-32 | 6.83e-01 | -0.0338 |
4830 | NME1 | brca2 | Human | Breast | Precancer | 1.19e-21 | 5.47e-01 | -0.024 |
4830 | NME1 | brca3 | Human | Breast | Precancer | 2.38e-06 | 4.15e-01 | -0.0263 |
4830 | NME1 | M1 | Human | Breast | IDC | 4.22e-08 | 4.70e-01 | 0.1577 |
4830 | NME1 | M2 | Human | Breast | IDC | 6.81e-07 | 4.67e-01 | 0.21 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00092067 | Breast | Precancer | purine ribonucleoside triphosphate biosynthetic process | 22/1080 | 68/18723 | 1.41e-11 | 1.88e-09 | 22 |
GO:00091457 | Breast | Precancer | purine nucleoside triphosphate biosynthetic process | 22/1080 | 69/18723 | 1.95e-11 | 2.43e-09 | 22 |
GO:00092017 | Breast | Precancer | ribonucleoside triphosphate biosynthetic process | 22/1080 | 74/18723 | 9.18e-11 | 1.00e-08 | 22 |
GO:00091448 | Breast | Precancer | purine nucleoside triphosphate metabolic process | 24/1080 | 88/18723 | 9.66e-11 | 1.03e-08 | 24 |
GO:00092057 | Breast | Precancer | purine ribonucleoside triphosphate metabolic process | 23/1080 | 82/18723 | 1.27e-10 | 1.34e-08 | 23 |
GO:00091427 | Breast | Precancer | nucleoside triphosphate biosynthetic process | 23/1080 | 85/18723 | 2.82e-10 | 2.69e-08 | 23 |
GO:00091997 | Breast | Precancer | ribonucleoside triphosphate metabolic process | 23/1080 | 89/18723 | 7.65e-10 | 6.66e-08 | 23 |
GO:00091418 | Breast | Precancer | nucleoside triphosphate metabolic process | 26/1080 | 112/18723 | 7.72e-10 | 6.66e-08 | 26 |
GO:00196938 | Breast | Precancer | ribose phosphate metabolic process | 49/1080 | 396/18723 | 3.81e-07 | 1.78e-05 | 49 |
GO:00091528 | Breast | Precancer | purine ribonucleotide biosynthetic process | 28/1080 | 169/18723 | 4.17e-07 | 1.89e-05 | 28 |
GO:00463907 | Breast | Precancer | ribose phosphate biosynthetic process | 30/1080 | 190/18723 | 4.75e-07 | 2.11e-05 | 30 |
GO:00092607 | Breast | Precancer | ribonucleotide biosynthetic process | 29/1080 | 182/18723 | 6.05e-07 | 2.55e-05 | 29 |
GO:00091509 | Breast | Precancer | purine ribonucleotide metabolic process | 46/1080 | 368/18723 | 6.47e-07 | 2.71e-05 | 46 |
GO:00091179 | Breast | Precancer | nucleotide metabolic process | 56/1080 | 489/18723 | 7.40e-07 | 3.00e-05 | 56 |
GO:00511019 | Breast | Precancer | regulation of DNA binding | 22/1080 | 118/18723 | 9.28e-07 | 3.71e-05 | 22 |
GO:00092598 | Breast | Precancer | ribonucleotide metabolic process | 47/1080 | 385/18723 | 9.69e-07 | 3.84e-05 | 47 |
GO:00469398 | Breast | Precancer | nucleotide phosphorylation | 20/1080 | 101/18723 | 1.07e-06 | 4.18e-05 | 20 |
GO:00067539 | Breast | Precancer | nucleoside phosphate metabolic process | 56/1080 | 497/18723 | 1.24e-06 | 4.70e-05 | 56 |
GO:00061639 | Breast | Precancer | purine nucleotide metabolic process | 47/1080 | 396/18723 | 2.14e-06 | 7.50e-05 | 47 |
GO:00433887 | Breast | Precancer | positive regulation of DNA binding | 14/1080 | 56/18723 | 2.46e-06 | 8.35e-05 | 14 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa009833 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa012404 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
hsa002404 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0124011 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
hsa0024011 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0123221 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0024021 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
hsa0124021 | Oral cavity | LP | Biosynthesis of cofactors | 57/2418 | 153/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 57 |
hsa0123231 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0024031 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
hsa0124031 | Oral cavity | LP | Biosynthesis of cofactors | 57/2418 | 153/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 57 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NME1 | SNV | Missense_Mutation | novel | c.244N>T | p.Asp82Tyr | p.D82Y | P15531 | protein_coding | deleterious(0) | possibly_damaging(0.748) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NME1 | SNV | Missense_Mutation | rs549666032 | c.92G>A | p.Arg31His | p.R31H | P15531 | protein_coding | tolerated(0.05) | benign(0.125) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NME1 | SNV | Missense_Mutation | rs749825423 | c.248G>A | p.Arg83His | p.R83H | P15531 | protein_coding | tolerated(0.14) | benign(0.013) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NME1 | SNV | Missense_Mutation | novel | c.293T>C | p.Val98Ala | p.V98A | P15531 | protein_coding | deleterious(0) | possibly_damaging(0.515) | TCGA-D1-A2G5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
NME1 | SNV | Missense_Mutation | rs765050521 | c.176N>A | p.Arg59His | p.R59H | P15531 | protein_coding | tolerated(0.09) | benign(0.019) | TCGA-4R-AA8I-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
NME1 | SNV | Missense_Mutation | c.461N>T | p.Glu154Val | p.E154V | P15531 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CC-A7IH-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
NME1 | SNV | Missense_Mutation | novel | c.142N>C | p.Glu48Gln | p.E48Q | P15531 | protein_coding | deleterious(0.05) | benign(0.118) | TCGA-60-2707-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | gemcitabine | PD |
NME1 | SNV | Missense_Mutation | novel | c.442N>A | p.Val148Met | p.V148M | P15531 | protein_coding | deleterious(0) | benign(0.347) | TCGA-XA-A8JR-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 7 | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4830 | NME1 | KINASE | tenofovir | TENOFOVIR | ||
4830 | NME1 | KINASE | lamivudine | LAMIVUDINE | ||
4830 | NME1 | KINASE | zidovudine | ZIDOVUDINE | 22960662 | |
4830 | NME1 | KINASE | LYCOPENE | LYCOPENE | 16140886 | |
4830 | NME1 | KINASE | adefovir dipivoxil |
Page: 1 |